Startseite Kongressberichte & Archiv The Gastrointestinal Cancers Symposium 2019 Breakout Session: Novel Innovations in Pancreatic and Hepatobiliary Malignancies

Breakout Session: Novel Innovations in Pancreatic and Hepatobiliary Malignancies

Ryan Fields, MD, FACS—Chair, Washington University School of Medicine in St. Louis

Maria Majella Doyle, MD, MBA
Washington University School of Medicine in St. Louis
Liver-Directed Therapy for Primary Hepatic Malignancies

Summary 
How do we choose which therapy?
• Ablation useful for Small tumors
  - Treatment and/or a bridge for HCC
  - IHC less known but more recurrence
• Small to medium sized tumors may consider chemoembolization or radioembolization
  - To Treat and/or Bridge
  - downstage to resection or to transplant
  - lncrease FLR (TARE)
• Many and large tumors should receive radioembolization and or TACE, if IHC consider HA Pump
  - To treat with or with out systemic
  - To downstage/size to resection
  - To downstage/size for transplant
• Preserved Liver function is essential for all treatments



Yuman Fong, MD
City of Hope
Advances in Minimally Invasive Surgery